Table 2.

Take-Home Messages.

COVID-19 disease imposes a hypercoagulable state with a higher incidence of VTE than other types of severe pneumonia In addition to their AC properties, heparins have an anti-inflammatory effect Guidelines recommend against monitoring D-dimer serial levels and increasing the dose intensity of AC depending on these levels Optimal thrombo-prophylaxis dose remains unclear For patients with mild symptoms related to COVID-19 disease, outpatient treatment or early discharge may be considered, with close follow-up Currently published guidelines suggest the use of prophylactic intensity over intermediate intensity or therapeutic intensity AC for patients with critical illness or acute illness related to SARS-COV-2 infection and who do not have suspected or confirmed DVT/PE In patients with an elevated risk for bleeding, including those with compromised renal function, UFH is preferred over LMWH or fondaparinux Critically ill patients with COVID-19 disease who are diagnosed with acute VTE are considered to have a provoking factor, and treatment duration should be at least 3 months For pregnant women with mild to moderate COVID-19 disease, mobilization, and management as an outpatient can be done

Abbreviations: VTE, venous thrombo-embolism; DVT/PE, deep venous thrombosis/pulmonary embolism; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; SARS-COV-2, severe acute respiratory syndrome coronavirus-2; AC, anticoagulation; COVID-19, coronavirus disease 2019.